243 related articles for article (PubMed ID: 32556496)
21. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
Ceppi F; Beck-Popovic M; Bourquin JP; Renella R
Eur J Pediatr; 2017 Sep; 176(9):1163-1172. PubMed ID: 28803259
[TBL] [Abstract][Full Text] [Related]
22. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study.
Wu X; Deng Z; Zhao Q
Front Immunol; 2022; 13():967076. PubMed ID: 36275770
[TBL] [Abstract][Full Text] [Related]
25. Advances in cancer immunotherapy 2019 - latest trends.
Kruger S; Ilmer M; Kobold S; Cadilha BL; Endres S; Ormanns S; Schuebbe G; Renz BW; D'Haese JG; Schloesser H; Heinemann V; Subklewe M; Boeck S; Werner J; von Bergwelt-Baildon M
J Exp Clin Cancer Res; 2019 Jun; 38(1):268. PubMed ID: 31217020
[TBL] [Abstract][Full Text] [Related]
26. Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.
Chen Y; Chen Y; Tan S; Zheng Y; Liu S; Zheng T; Mi Y; Lin S; Yang C; Li W
Hum Vaccin Immunother; 2023 Dec; 19(1):2186684. PubMed ID: 37017186
[TBL] [Abstract][Full Text] [Related]
27. A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022.
Zhang J; Chen P; Miao L
Front Immunol; 2022; 13():969196. PubMed ID: 36032149
[TBL] [Abstract][Full Text] [Related]
28. Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis.
Su Y; Ruan Z; Wang R; Hao S; Tang Y; Huang X; Gao T; Li Z; Chang T
Front Immunol; 2022; 13():998217. PubMed ID: 36248874
[TBL] [Abstract][Full Text] [Related]
29. Preface: More than two decades of modern tumor immunology.
Galluzzi L; Rudqvist NP
Methods Enzymol; 2020; 632():xxiii-xlii. PubMed ID: 32000917
[No Abstract] [Full Text] [Related]
30. Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022.
Qu F; Wang G; Wen P; Liu X; Zeng X
Hum Vaccin Immunother; 2024 Dec; 20(1):2335728. PubMed ID: 38563136
[TBL] [Abstract][Full Text] [Related]
31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA; Soyano AE; Dholaria B; Knutson KL; Lou Y
J Hematol Oncol; 2018 Jan; 11(1):8. PubMed ID: 29329556
[TBL] [Abstract][Full Text] [Related]
33. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
34. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
Front Immunol; 2022; 13():975695. PubMed ID: 36148235
[TBL] [Abstract][Full Text] [Related]
35. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.
Liu YG; Jiang ST; Zhang L; Zheng H; Zhang T; Zhang JW; Zhao HT; Sang XT; Xu YY; Lu X
Eur J Med Res; 2023 Jul; 28(1):229. PubMed ID: 37430294
[TBL] [Abstract][Full Text] [Related]
36. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
37. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
Ascierto PA; Bifulco C; Buonaguro L; Emens LA; Ferris RL; Fox BA; Delgoffe GM; Galon J; Gridelli C; Merlano M; Nathan P; Odunsi K; Okada H; Paulos CM; Pignata S; Schalper KA; Spranger S; Tortora G; Zarour H; Butterfield LH; Puzanov I
J Immunother Cancer; 2019 Nov; 7(1):332. PubMed ID: 31783779
[TBL] [Abstract][Full Text] [Related]
38. Unveiling the Research Landscape and Emerging Trends in Cell Cycle for Cancer Immunotherapy: A Bibliometric Analysis (1990-2022).
Feng C; Li Y; Zang M; Jin-Si-Han EE; He M; Lu Z
Med Sci Monit; 2023 Dec; 29():e940556. PubMed ID: 38037303
[TBL] [Abstract][Full Text] [Related]
39. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
[TBL] [Abstract][Full Text] [Related]
40. Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.
Zheng W; Wu Y; Wang Y; Cheng J; Shen W
Medicine (Baltimore); 2023 Jul; 102(27):e34228. PubMed ID: 37417594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
